The pharmaceutical giant GSK today announced a £200 million investment programme that it says will support a pipeline of new medicines and create a centre for pharmaceutical manufacturing innovation in the UK.
Manufacturing sites in Ware, Hertfordshire and Worthing, Sussex will be upgraded with new state-of-the-art equipment. In addition GSK said it will establish a new facility dedicated to harnessing innovative technologies “with the potential to transform both the way medicines are made and the company’s supply chain”.
GSK’s global manufacturing boss Roger Connor said the establishment of what the company calls ‘the Patent Box’ had transformed its view of the UK as a place to invest. He went on: “As a result, last year we announced we were building our first new factory in the UK for 40 years. The investments announced today are in addition to that and will allow us to harness new technologies that have the potential to deliver a step-change in how we make medicines. These new technologies could significantly reduce costs, improve quality and enable the manufacture of medicines in weeks rather than years and I am delighted that we have been able to bring these investments to the UK.”
The new investments comprise:
– New manufacturing facilities in Ware for the latest inhaler devices.
– In Worthing, a new bulk sterile building and filling line will be built for the company’s leading antibiotic medicine.
– A new centre for manufacturing innovation will be built, dedicated to technologies ranging from mimicking nature to using nano-technologies. GSK’s preferred site for the location of the new centre is Ware, Hertfordshire where the company already has manufacturing and R&D facilities.
Copyright Ken Hurst 2013